DrugPatentWatch Database Preview
Eli Lilly And Co Company Profile
» See Plans and Pricing
What is the competitive landscape for ELI LILLY AND CO, and when can generic versions of ELI LILLY AND CO drugs launch?
ELI LILLY AND CO has six approved drugs.
There are fifteen US patents protecting ELI LILLY AND CO drugs.
There are two hundred and thirty-two patent family members on ELI LILLY AND CO drugs in fifty-two countries and thirty-two supplementary protection certificates in fifteen countries.
Summary for Eli Lilly And Co
| International Patents: | 232 |
| US Patents: | 15 |
| Tradenames: | 7 |
| Ingredients: | 6 |
| NDAs: | 6 |
| Drug Master File Entries: | 37 |
| Patent Litigation for Eli Lilly And Co: | See patent lawsuits for Eli Lilly And Co |
| PTAB Cases with Eli Lilly And Co as petitioner: | See PTAB cases with Eli Lilly And Co as petitioner |
| PTAB Cases with Eli Lilly And Co as patent owner: | See PTAB cases with Eli Lilly And Co as patent owner |
Drugs and US Patents for Eli Lilly And Co
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-002 | Sep 28, 2017 | RX | Yes | No | Start Trial | Start Trial | |||||
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-001 | Sep 28, 2017 | RX | Yes | No | Start Trial | Start Trial | |||||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | RX | Yes | No | Start Trial | Start Trial | |||||
| Eli Lilly And Co | AXIRON | testosterone | SOLUTION, METERED;TRANSDERMAL | 022504-001 | Nov 23, 2010 | DISCN | Yes | No | 8,435,944 | Start Trial | Start Trial | ||||
| Eli Lilly And Co | SARAFEM | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-008 | Jul 6, 2000 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Eli Lilly And Co | SARAFEM | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-007 | Jul 6, 2000 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-003 | Sep 28, 2017 | RX | Yes | No | 7,855,211 | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Eli Lilly And Co
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | AXIRON | testosterone | SOLUTION, METERED;TRANSDERMAL | 022504-001 | Nov 23, 2010 | 6,818,226 | Start Trial |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-003 | Jun 15, 1999 | 6,960,577 | Start Trial |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,647,591 | Start Trial |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-004 | Jun 15, 1999 | 4,314,081*PED | Start Trial |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,590,213 | Start Trial |
| Eli Lilly And Co | SARAFEM | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-007 | Jul 6, 2000 | 4,971,998*PED | Start Trial |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,314,081*PED | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ELI LILLY AND CO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Topical Solution | 30 mg/1.5 mL | ➤ Subscribe | 2013-01-29 |
International Patents for Eli Lilly And Co Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Singapore | 11201705640P | Start Trial |
| Peru | 20171334 | Start Trial |
| South Korea | 20130114229 | Start Trial |
| Slovenia | 2379528 | Start Trial |
| Morocco | 41547 | Start Trial |
| Eurasian Patent Organization | 201791560 | Start Trial |
| China | 107278154 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Eli Lilly And Co Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2379528 | 132019000000037 | Italy | Start Trial | PRODUCT NAME: ABEMACICLIB(VERZENIOS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1307, 20181001 |
| 2288610 | 2017C/025 | Belgium | Start Trial | PRODUCT NAME: OLUMIANT - BARICITINIB; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215 |
| 2288610 | 1790035-8 | Sweden | Start Trial | PRODUCT NAME: BARICITINIB; REG. NO/DATE: EU/1/16/1170 20170215 |
| 2288610 | 122017000045 | Germany | Start Trial | PRODUCT NAME: BARICITINIB; REGISTRATION NO/DATE: EU/1/16/1170 20170213 |
| 2288610 | C20170022 00232 | Estonia | Start Trial | PRODUCT NAME: BARITSITINIIB;REG NO/DATE: EU/1/16/1170 15.02.2017 |
| 2379528 | 122019000010 | Germany | Start Trial | PRODUCT NAME: ABEMACICLIB; REGISTRATION NO/DATE: EU/1/18/1307 20180927 |
| 2288610 | 2017033 | Norway | Start Trial | PRODUCT NAME: BARICITINIB OG FARMASOEYTISK; REG. NO/DATE: EU/1/16/1170 20170222 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
